- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05167253
A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.
A Phase I, Open-label Study to Evaluate the Ability of UB-612 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines
Study Overview
Detailed Description
This is a phase I, open-label clinical study to evaluate the ability of UB-612 vaccine to boost immunity of subjects who previously received two doses of AstraZeneca COVID-19 vaccine (ChAdOx1-S) with an 8-16 week interval between first and second doses.
This study will enroll approximately 30 subjects aged 20 to 55 years. The previous COVID-19 vaccine series will have been completed at least six months before study enrollment. Both sexes should be evenly distributed in subjects.
Subjects will be enrolled to receive one dose of 100 μg UB-612 vaccine at Day 1. The subjects will come to the clinics at Visit 1 (screening, Day -28 to -1), Visit 2 (Day 1, vaccination), Visit 3 (Day 15, 14 days after vaccination), Visit 4 (Day 29, 28 days after vaccination), Visit 5 (Day 169, 6 months after vaccination) and will receive phone calls at 7 days after vaccination for safety check.
Study Type
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male or non-pregnant female between the age of 20 and 55 years at time of enrolment.
- Fully vaccinated with two injections of AstraZeneca COVID-19 vaccine (ChAdOx1-S) with an 8-16 week interval between first and second doses. The second dose of AstraZeneca COVID-19 vaccine (ChAdOx1-S) must have been administered more than six (6) months from study Day 1. The CDC COVID-19 Vaccination Record Card or appropriate documentation (e.g., medical records) will be required for documentation.
- Women of childbearing potential and men must agree to practice medically effective contraception from vaccination until 30 days after the vaccination.
- Participant or the participant's legal representative must understand the procedures of the study and is willing to sign the Informed Consent Form (ICF).
- Able to understand and agrees to comply with all study procedures and be available for all study visits.
- Must be able to read, understand, and complete the protocol-required questionnaires and/or diary.
- Negative serological test for Hepatitis B surface antigen (HBsAg), HCV RNA and HIV antibody
- Negative results of SARS-CoV-2 N protein IgG ELISA
- Negative result of RT-PCR screening of nasopharyngeal or throat swabs for SARS-CoV-2.
- Ear temperature ≤ 38.0°C.
- Indexes of hematology, biochemistry and immunology laboratory tests are within the normal ranges, or not clinically significant as judged by investigators
Exclusion Criteria:
- History of anaphylaxis, urticarial, or other significant adverse reaction requiring medical intervention after receipt of a vaccine.
- Female who is pregnant or positive in pregnancy test at screening or just prior to vaccination administration or plans to become pregnant from the time of study vaccination through 30 days after the administration of the study vaccine.
- Female who is breast-feeding or plans to breastfeed from the time of the study vaccination through 30 days after the administration of the study vaccine.
- Investigational non-coronavirus vaccines: previous receipt of an investigational vaccine (non-coronavirus) within 1 year before the planned administration of study vaccine.
- Prior administration of attenuated, nucleic acid (mRNA or DNA) or vectored vaccines in last 1 month before the study vaccine or expectation of such vaccines in the month after the study vaccine.
- Prior administration of subunit vaccine or inactivated vaccine in last 14 days before the study vaccine or expectation of receipt of such vaccines in the 14 days after the study vaccine.
- Judged by the investigator on the basis of evidence or medical history, immunosuppressive or immunodeficient state, autoimmune diseases, chronic kidney disease (with dialysis), asplenia, or recurrent severe infections.
- Prior chronic administration of immunosuppressant or corticosteroids, cytotoxic treatment in last 6 months before the study vaccination.
- Receipt of short-term systemic corticosteroids. Study intervention administration should be delayed until systemic corticosteroid use has been discontinued for at least 28 days. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
- Has received systemic immunoglobulins or blood products within 4 months prior to enrollment.
- Loss or donation of blood over 500 mL within 3 months prior to screening visit or intention to donate blood or blood products for transfusion during the study.
- Participants who received specific anti-SARS-CoV-2 monoclonal antibody products at any time.
- Subjects who take part in another clinical study and are currently receiving or received any investigational intervention within 12 weeks prior to the day of informed consent.
- Platelet disorder or other bleeding disorder may cause injection contraindication.
- Any acute illness, as determined by the study investigator 3 days before vaccination.
- Judged by the investigator on the basis of evidence or medical history, participants with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies) will be excluded.
- History of malignancy within 5 years prior to screening visit, except basal cell carcinoma of the skin and cervical carcinoma in situ.
- Known history of SARS, MERS or SARS-CoV-2 infection.
- Alcoholism or substance abuser.
- Behavioral, cognitive, or psychiatric disease that, in the opinion of investigators, affects the participant's ability to understand and cooperate with all study protocol requirements.
- Employees at the investigator's site, of the Sponsor or the contract research organization (CRO) directly involved in the conduct of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: UB-612 100 μg, 0.5 mL
All subjects will be enrolled to receive one dose of 100 μg UB-612 vaccine
|
UB-612 includes a designer S1-RBD-sFc fusion protein formulated with designer Th and CTL epitope peptides selected from immunodominant M, S2 and N regions known to bind to human MHC I and II.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability
Time Frame: within 7 days after vaccination
|
|
within 7 days after vaccination
|
Safety and tolerability
Time Frame: 28 days after vaccination
|
• Unsolicited adverse events
|
28 days after vaccination
|
Immunogenicity
Time Frame: 14 days after vaccination
|
• Geometric mean titers (GMT) of neutralizing antibody against SARS-CoV-2 wild type
|
14 days after vaccination
|
Immunogenicity
Time Frame: 14 days after vaccination
|
• Seroconversion rate (SCR) of neutralizing antibody against SARS-CoV-2 wild type
|
14 days after vaccination
|
Immunogenicity
Time Frame: 14 days after vaccination
|
• Geometric mean fold increase (GMFI) of neutralizing antibody against SARS-CoV-2 wild type
|
14 days after vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: Day 1
|
|
Day 1
|
Safety
Time Frame: 14 days after vaccination
|
|
14 days after vaccination
|
Safety
Time Frame: 28 days after vaccination
|
|
28 days after vaccination
|
Safety
Time Frame: 6 months after vaccination
|
|
6 months after vaccination
|
Evaluation of safety of hematology and biochemistry
Time Frame: Pre-vaccination
|
Change of safety laboratory measurement from pre-vaccination
|
Pre-vaccination
|
Immunogenicity
Time Frame: 14 days after vaccination
|
• GMT of neutralizing antibody against SARS-CoV-2 wild type, antigen-specific antibody titers (anti-S1-RBD), S1-RBD:ACE2 binding inhibition antibody
|
14 days after vaccination
|
Immunogenicity
Time Frame: 14 days after vaccination
|
• SCR of neutralizing antibody against SARS-CoV-2 wild type, , antigen-specific antibody titers (anti-S1-RBD), S1-RBD:ACE2 binding inhibition antibody
|
14 days after vaccination
|
Immunogenicity
Time Frame: 14 days after vaccination
|
• GMFI of neutralizing antibody against SARS-CoV-2 wild type, , antigen-specific antibody titers (anti-S1-RBD), S1-RBD:ACE2 binding inhibition antibody
|
14 days after vaccination
|
Immunogenicity
Time Frame: 28 days after vaccination
|
• GMT of neutralizing antibody against SARS-CoV-2 wild type, antigen-specific antibody titers (anti-S1-RBD), S1-RBD:ACE2 binding inhibition antibody
|
28 days after vaccination
|
Immunogenicity
Time Frame: 28 days after vaccination
|
• SCR of neutralizing antibody against SARS-CoV-2 wild type, antigen-specific antibody titers (anti-S1-RBD), S1-RBD:ACE2 binding inhibition antibody
|
28 days after vaccination
|
Immunogenicity
Time Frame: 28 days after vaccination
|
• GMFI of neutralizing antibody against SARS-CoV-2 wild type, , antigen-specific antibody titers (anti-S1-RBD), S1-RBD:ACE2 binding inhibition antibody
|
28 days after vaccination
|
Immunogenicity
Time Frame: 6 months after vaccination
|
• GMT of neutralizing antibody against SARS-CoV-2 wild type, , antigen-specific antibody titers (anti-S1-RBD), S1-RBD:ACE2 binding inhibition antibody
|
6 months after vaccination
|
Immunogenicity
Time Frame: 6 months after vaccination
|
• SCR of neutralizing antibody against SARS-CoV-2 wild type, , antigen-specific antibody titers (anti-S1-RBD), S1-RBD:ACE2 binding inhibition antibody
|
6 months after vaccination
|
Immunogenicity
Time Frame: 6 months after vaccination
|
• GMFI of neutralizing antibody against SARS-CoV-2 wild type, , antigen-specific antibody titers (anti-S1-RBD), S1-RBD:ACE2 binding inhibition antibody
|
6 months after vaccination
|
Immunogenicity
Time Frame: 14 days after vaccination
|
• GMT of neutralizing antibody titers against SARS-CoV-2 variant
|
14 days after vaccination
|
Immunogenicity
Time Frame: 14 days after vaccination
|
• SCR of neutralizing antibody titers against SARS-CoV-2 variant
|
14 days after vaccination
|
Immunogenicity
Time Frame: 14 days after vaccination
|
• GMFI of neutralizing antibody titers against SARS-CoV-2 variant
|
14 days after vaccination
|
Immunogenicity
Time Frame: 14 days after vaccination
|
• Reduction fold of GMT compared with neutralizing antibody titers against SARS-CoV-2 wild type
|
14 days after vaccination
|
Immunogenicity
Time Frame: 28 days after vaccination
|
• GMT of neutralizing antibody titers against SARS-CoV-2 variant
|
28 days after vaccination
|
Immunogenicity
Time Frame: 28 days after vaccination
|
• SCR of neutralizing antibody titers against SARS-CoV-2 variant
|
28 days after vaccination
|
Immunogenicity
Time Frame: 28 days after vaccination
|
• GMFI of neutralizing antibody titers against SARS-CoV-2 variant
|
28 days after vaccination
|
Immunogenicity
Time Frame: 28 days after vaccination
|
• Reduction fold of GMT compared with neutralizing antibody titers against SARS-CoV-2 wild type
|
28 days after vaccination
|
Immunogenicity
Time Frame: Day 1
|
• T cell responses
|
Day 1
|
Immunogenicity
Time Frame: 14 days after vaccination
|
• T cell responses
|
14 days after vaccination
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- V-125
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on UB-612
-
United Biomedical Inc., AsiaVaxxinity, Inc.Completed
-
Vaxxinity, Inc.Diagnósticos da América S/A (DASA)WithdrawnCovid-19 | SARS-CoV-2 | Coronavirus
-
United Biomedical Inc., AsiaVaxxinity, Inc.Terminated
-
United Biomedical Inc., AsiaVaxxinity, Inc.Completed
-
AstraZenecaCompletedLPS Challenge, NeutrophilsUnited Kingdom
-
Vaxxinity, Inc.Syneos Health; Coalition for Epidemic Preparedness InnovationsActive, not recruitingCOVID-19 VaccinesPhilippines, United States, Panama
-
Sinew Pharma Inc.TerminatedNASH - Nonalcoholic SteatohepatitisTaiwan
-
UBP Greater China (Shanghai) Co., LtdNot yet recruiting
-
UBP Greater China (Shanghai) Co., LtdNot yet recruitingChronic Spontaneous Urticaria
-
United BioPharmaTaipei Veterans General Hospital, TaiwanCompletedHerpes Simplex Virus InfectionTaiwan